While cART improves immune function by increasing CD4+ T-cells and reducing viral load, chronic immune activation persists, particularly in CD8+ T-cells, driving B-cell dysregulation and promoting lymphoma development [18,19,20]. This evidence concerns the gene CD4 and lymphoma.